Novartis projects strong growth and market impact with the launch of Scemblix as an alternative treatment for CML patients facing access challenges.
PSFK Earnings Call: Novartis - NVS
PSFK Earnings Call: Novartis - NVS
PSFK Earnings Call: Novartis - NVS
Novartis projects strong growth and market impact with the launch of Scemblix as an alternative treatment for CML patients facing access challenges.